Chemtrail Culprits Identified?
BioWarfare Countermeasures
Being Tested?

Note: We originally alerted you to some of this incredible
information about Chemtrails/Aerial Vaccines last month.
Check here

Warfare Chemicals being Tested: The strange-looking streaks in the sky aren't your imagination.
They are anti-bacteriological warfare chemicals being tested by the federal government. And the public has been kept in the dark.
The chemical spraying to the "unconventional pathogen countermeasures program" of the top secret Defense Advanced Research Projects Agency (DARPA).
NOTE : Novavax is a bio pharmaceuticals company. BCTP is made of water, soybean oil, Triton X 100 detergent and the solvent tri-n-butyl phosphate. BCTP envelops the VIRUSES and SPORES, causing them to explode and thus destroying them upon contact.
********* Novavax, Inc. :
NOTE : BCTP's research studies were funded by the Defense Advanced Research Projects Agency (DARPA).
BCTP appears to inactivate the virus on contact."
The research is funded by DARPA's "Unconventional Pathogen Countermeasures Program"
[GO TO : ]. The U-M and Novavax have filed a patent application covering BCTP's use as a decontamination agent for various anti-microbial applications.
*** There IS an "Alien" INVADER Biological THREAT! Research and Development Areas :
Advanced Biological and Medical Technologies: Biological Warfare Defense Unconventional Pathogen Countermeasures
The goal of the Unconventional Pathogen Countermeasures program is to develop and demonstrate defensive technologies that afford the greatest protection to uniformed warfighters, and the defense personnel who support them, during U.S. military operations. While no defense may stop a determined adversary from unleashing biological weapon, a sufficiently robust array of pathogen defenses and countermeasures ,Äî deterrents in their own right ,Äî will reduce the probable damage that would result from biological weapons used in a particular operation.
The most sinister offensive biological warfare scenario employs surprise, immediate proximity, and rapidly lethal, persistent agents in overwhelming quantities. Under these circumstances, real-time sensing, donning of physical protection, and conventional nonmedical countermeasures are only marginally effective. An effective operational defense ideally requires instantly available or emplaced countermeasures that can defeat biological threats as they enter the body and before they reach and attack target cells and tissues.
The focus of the Unconventional Pathogen Countermeasures program is the development of revolutionary, broad-spectrum, medical countermeasures against significantly pathogenic microorganisms and/or their pathogenic products. These countermeasures will be versatile enough to eliminate biological threats, whether from natural sources or modified through bioengineering or other manipulation. They will also have the potential to provide protection both within the body and at the most common portals of entry (e.g., inhalation, ingestion, transcutaneous). Strategies include but are not limited to:
Defeat of a pathogen's ability to enter the body, traverse the bloodstream or lymphatics, and enter target tissues.
Identification of novel pathogen vulnerabilities based on fundamental, critical molecular mechanisms of survival or pathogenesis (e.g., Type III secretion, cellular energetics, virulence modulation).
Construction of unique, robust vehicles for the delivery of countermeasures into or within the body.
Modulation of the advantageous and/or deleterious aspects of the immune response to significantly pathogenic microorganisms and/or their pathogenic products in the body. *******************************
Excerpted from:
A great many people throughout Europe and other Plague stricken regions of the world were reporting that outbreaks of the Plague were caused by foul-smelling "mists". Those mists frequently appeared after unusually bright lights in the sky. The historian quickly discovers that "mists" were reported far more frequently and in many more locations than were rodent infestations. The Plague years were, in fact, a period of heavy UFO activity.
LUCAS : Flu comes from Outer Space, claim scientists
Excerpted from : In a report to be published in the journal Current Science, they claim the outbreak was caused by dust deposited high in the atmosphere by passing comets being forced down to earth by energy generated by cooler patches on the sun's surface, known as sunspots. * In a report to be published in the journal Current Science, they claim the outbreak was caused by DUST deposited high in the atmosphere by passing comets being forced down to earth by energy generated by cooler patches on the sun's surface, known as sunspots.
They reach the peak of their activity, the maxima, every 11 years... The latest cycle began to peak in September and the maxima is due sometime this year.
-- Bill Hamilton Executive Director Skywatch International, Inc. Website:
And furthermore:
Maxygen Announces $6.7 Million Grant
from DARPA to Develop Aerosolized Vaccines
Redwood City, CA, September 28, 1999. Maxygen announced today that it has received a $6.7 million three-year grant from the Defense Advanced Research Agency (DARPA) to use its proprietary MolecularBreeding directed evolution technology (also known as "DNA Shuffling") to develop aerosol-based vaccines to protect against a broad spectrum of pathogens.
Aerosol delivery of prophylactic and therapeutic agents is potentially the simplest and most cost-effective way to protect or treat humans and animals from disease epidemics. In addition to this recent DARPA grant, Maxygen is the recipient of two additional DARPA grants in the vaccine area. In February 1998, Maxygen received a $5.6 million grant to evolve novel DNA vectors for efficient delivery and expression of pathogen antigens, and in April 1999, the Company received a grant of $7.7 million to generate novel vaccine antigens for a wide range of pathogens.
Maxygen, Inc., headquartered in Redwood City, CA is a private biotechnology company that is focused on the development of novel and improved commercial products using its proprietary MolecularBreeding directed evolution technology for a variety of industries including human therapeutics, chemicals, vaccines, industrial enzymes, and agriculture. The Company is the leader in nucleic acid recombination technologies for imparting new properties into single genes, multi-gene systems, pathways, vectors and genomes. Maxygen has commercial relationships with several companies including Novo Nordisk in certain areas of industrial enzymes, Pioneer Hi-Bred and ZenecaAgrochemicals for specific products in agriculture and DSM Anti-Infectives for improved manufacturing of certain classes of penicillin antibiotics. Maxygen was founded in a March 1997 spinout from Glaxo Wellcome-Affymax, led by biotech entrepreneur Alejandro Zaffaroni, and MolecularBreeding inventor Pim Stemmer.
NovaVax Denies Role In Chemtrials 1-28-00
(NovaVax was asked about the chemtrail issue. Here is the company's response...)
In response to your question regarding our testing an agent on the American Public. Rest assured that we ARE NOT testing ANY agent on the American Public.
We are in the business of researching and developing drug delivery platforms (specifically transdermal in the form of a hand cream) not drugs or chemical agents. Our product is currently being tested in a controlled clinical study. The drug being used in our platform is Estradiol. We are also collaborating on many types of vaccines, such as influenza and human HPV.
I hope this will alleviate your concerns about our company. If you have any further questions please contact us again.
If at all possible I would appreciate your providing us with the source of your information.
Jessica F. Gandy Controller/Human Resources


This Site Served by TheHostPros